Clinical Trials Browser

Withdrawn × Leukemia, Myeloid, Acute × Cytarabine × Clear all

NCT05521087 2025-06-22

A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05829434 2024-02-12

MAGROLIC

Phase 2 Withdrawn

Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT05456269 2023-10-03

BISECT

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05320380 2023-09-01

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Phase 1/2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04354025 2023-04-04

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00003407 2023-02-02

Amifostine & High-Dose Combination Chemotherapy in Treating Patients With Acute ML or CML

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Drug-Related Side Effects and Adverse Reactions

NCT00003405 2021-10-14

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

NCT00004114 2020-07-31

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase 1 Withdrawn

DermatologicLymphoidMyeloidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Myelodysplastic Syndromes, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03760445 2020-01-09

HDM201 Added to CT in R/R or Newly Diagnosed AML

Phase 1/2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03207334 2018-10-22

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Phase 2 Withdrawn

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT02718755 2018-06-26

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Lymphoma, Recurrence, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02680951 2018-04-19

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02791919 2017-05-03

Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01843179 2017-02-17

Sulindac for Patients With AML

Phase 2 Withdrawn

Other hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT01067274 2015-12-30

ALFA-0703

Phase 3 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00411281 2015-09-30

Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder

Phase 3 Withdrawn

MyeloidOther hematologic neoplasm

Myeloproliferative Syndrome, Transient, Leukemia, Leukemia, Myeloid, Acute

NCT00967512 2014-09-18

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT01478074 2014-01-03

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

Phase 1 Withdrawn

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00594555 2008-10-31

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

Phase 2 Withdrawn

MyeloidOther hematologic neoplasm

Blast Crisis, Hematologic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute